country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-W745845

Copy Link Print Information

Simendan

Name: Simendan
Brand: MedChemExpress
SKU: HY-W745845
Availability: PreOrder

(別名: (rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259)

Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) is a calcium-sensitizing positive inotropic vasodilator compound that enhances myocardial contractility through calcium-dependent binding to cardiac troponin C and selectively inhibits cardiac phosphodiesterase (Phosphodiesterase) III, while inducing coronary and peripheral vasodilation and anti-ischemic effects. Simendan can be used for research on congestive heart failure, acute heart failure, myocardial infarction, myocardial ischemia, and thrombotic diseases.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 131741-08-7
分子式: C₁₄H₁₂N₆O
分子量:280.28

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Simendan 構造式

CAS 番号: 131741-08-7

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Phosphodiesterase (PDE) アイソフォーム固有の製品をすべて表示 :

体外実験

Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) selectively inhibits cardiac phosphodiesterase III in purified enzyme preparations^[1].
Simendan binds to cardiac troponin C in a calcium-dependent manner in paced papillary muscle preparations, combining positive inotropic effects with enhanced cardiac relaxation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

体内実験

Simendan ((rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259) (2.5 mg/kg; p.o.; free access; 312 days) improves survival in rats with post-myocardial infarction healing, with a mortality rate of 53% at 312 days, representing a 28% risk reduction compared with the control group^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (Male, 300-350 g, healed myocardial infarction via left anterior descending coronary artery ligation)^[3]
Dosage:

2.5 mg/kg
Administration:

p.o.; ad libitum; 312 days
Result:

Reduced mortality rate to 53% at day 312, representing a 28% risk reduction versus control.
Reduced 6-month mortality rate to 19%.
Achieved an infarct size of 43%.
Histological analysis showed an external normal boundary of 11.9 mm, internal normal boundary of 7.6 mm, external infarct boundary of 7.4 mm, internal infarct boundary of 6.2 mm, whole area of 60.7 mm², normal area of 52.4 mm², and infarct area of 8.2 mm².

化学情報

CAS 番号 131741-08-7
分子量 280.28
分子式 C₁₄H₁₂N₆O
SMILES

N#C/C(C#N)=N/NC1=CC=C(C2=NNC(CC2C)=O)C=C1
別名

(rac)-Levosimendan; (rac)-Simsndan; (rac)-OR-1259
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

プロトコル

All Signal Pathway Related

Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.

純度とドキュメンテーション

取扱説明書 (2659 KB)

参考文献

[1]. Lilleberg J, et al. Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. Clinical pharmacology and therapeutics. 1994 Nov;56(5):554-63.

[2]. Lilleberg JM, et al. Hemodynamic effects of the novel cardiotonic drug simendan: echocardiographic assessment in healthy volunteers. Cardiovascular drugs and therapy. 1994 Apr;8(2):263-9.

[3]. Levijoki J, et al. Improved survival with simendan after experimental myocardial infarction in rats. European journal of pharmacology. 2001 May 11;419(2-3):243-8.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ